Denosumab associated with bone density increase and clinical improvement in a long-term hemodialysis patient. Case report and review of the literature.
Acta Medica (Hradec Kralove)
; 57(1): 30-3, 2014.
Article
en En
| MEDLINE
| ID: mdl-25006661
ABSTRACT
Denosumab is a human monoclonal antibody representing a novel therapy of osteoporosis. Contrary to always other antiosteoporotic drugs, it is not contraindicated in advanced chronic kidney disease, as its pharmacokinetic does not differ from patients with normal kidney function. However, published case reports in chronic kidney disease (CKD) patients stopped the therapy after single dose because of hypocalcemia. We present a case of successful treatment of osteoporosis in a young hemodialysis patient with repeated denosumab doses.
Palabras clave
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Osteoporosis
/
Diálisis Renal
/
Conservadores de la Densidad Ósea
/
Anticuerpos Monoclonales Humanizados
/
Fallo Renal Crónico
Tipo de estudio:
Risk_factors_studies
Límite:
Adult
/
Female
/
Humans
Idioma:
En
Revista:
Acta Medica (Hradec Kralove)
Asunto de la revista:
MEDICINA
Año:
2014
Tipo del documento:
Article
País de afiliación:
República Checa